Nirsum has developed a series of novel small molecule candidates with potential utility in treating addiction to opioids, alcohol, methamphetamines, as well as other conditions. Our most advanced compound NRS-033 is an internally discovered, wholly owned, and US patented novel composition, currently undergoing Phase 1 clinical trials.  NRS-033 development is funded in part through a Cooperative Agreement with the United States National Institutes of Health (HEAL Initiative award UG3DA048234).